suramin   Click here for help

GtoPdb Ligand ID: 1728

Synonyms: CI-1003 | suramine
Approved drug PDB Ligand
suramin is an approved drug
Compound class: Synthetic organic
Comment: Suramin is an antiparasitic drug. It is also used in research as a broad-spectrum P2 receptor antagonist [1,5] and as a ryanodine receptor agonist [13].
Evidence from studies in mice [7-9], and from an early phase clinical trial suggest antipurinergic therapy (using suramin or other antipurinergic compounds) as a potential lead in the search for pharmacotherapeutic intervention in children with autism spectrum disorder (see Phase 1/2 clinical trial NCT02508259).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 29
Hydrogen bond donors 12
Rotatable bonds 22
Topological polar surface area 534.03
Molecular weight 1296.05
XLogP 0.91
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O
Isomeric SMILES O=C(Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O
InChI InChI=1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)
InChI Key FIAFUQMPZJWCLV-UHFFFAOYSA-N
References
1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA et al.. (2006)
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.
Pharmacol Rev, 58 (3): 281-341. [PMID:16968944]
2. Communi D, Robaye B, Boeynaems JM. (1999)
Pharmacological characterization of the human P2Y11 receptor.
Br J Pharmacol, 128 (6): 1199-206. [PMID:10578132]
3. Jacobson KA, Jarvis MF, Williams M. (2002)
Purine and pyrimidine (P2) receptors as drug targets.
J Med Chem, 45 (19): 4057-93. [PMID:12213051]
4. Janssens R, Paindavoine P, Parmentier M, Boeynaems JM. (1999)
Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants.
Br J Pharmacol, 127 (3): 709-16. [PMID:10401562]
5. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Séguéla P, Voigt M, Humphrey PP. (2001)
International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits.
Pharmacol Rev, 53 (1): 107-18. [PMID:11171941]
6. Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, Boeynaems JM, Gonzalez NS. (2003)
Pharmacological characterization of the human P2Y13 receptor.
Mol Pharmacol, 64 (1): 104-12. [PMID:12815166]
7. Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, Naviaux RK. (2014)
Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy.
Transl Psychiatry, 4: e400. [PMID:24937094]
8. Naviaux JC, Wang L, Li K, Bright AT, Alaynick WA, Williams KR, Powell SB, Naviaux RK. (2015)
Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.
Mol Autism, 6: 1. [PMID:25705365]
9. Naviaux RK, Zolkipli Z, Wang L, Nakayama T, Naviaux JC, Le TP, Schuchbauer MA, Rogac M, Tang Q, Dugan LL et al.. (2013)
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model.
PLoS ONE, 8 (3): e57380. [PMID:23516405]
10. Schachter JB, Harden TK. (1997)
An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor.
Br J Pharmacol, 121 (2): 338-44. [PMID:9154346]
11. von Kügelgen I, Hoffmann K. (2016)
Pharmacology and structure of P2Y receptors.
Neuropharmacology, 104: 50-61. [PMID:26519900]
12. Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA, Harden TK. (2002)
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.
Mol Pharmacol, 62 (5): 1249-57. [PMID:12391289]
13. Wolner I, Kassack MU, Ullmann H, Karel A, Hohenegger M. (2005)
Use-dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676.
Br J Pharmacol, 146 (4): 525-33. [PMID:16056233]